ACR (美国风湿病学会) is a society covering all immune-related diseases, and this year's conference is scheduled to be held at the 圣迪亚哥会议中心 from November 10 to 15.
This 壁报发表 will feature 临床前结果 for an 骨关节炎 pain-inhibiting compound, part of RudaCure's RCI002 project currently under development. The results to be presented demonstrate pain suppression for up to two weeks following a single administration.
Through formulation research, this compound is expected to be applicable not only for 骨关节炎 but also for degenerative disc disease (cervical and lumbar spine, etc.) with administration once every six months or once a year.
